On Thursday, the Food and Drug Administration (FDA) revealed the first nine recipients of the Commissioner’s National Priority Review vouchers. This program aims to expedite the drug review process for companies whose products align with national health priorities.
Overview of the Priority Review Vouchers
The Priority Review vouchers are designed to encourage the development of drugs that address critical health needs. Companies receiving these vouchers can expedite the FDA review process for one of their drugs, thus bringing essential therapies to market more quickly.
Notable Recipients
Among the highlighted recipients is EMD Serono, a company acknowledged during a White House news conference. President Trump emphasized their commitment to enhancing access to in vitro fertilization.
- EMD Serono: Received a voucher for Pergoveris, a fertility drug that stimulates egg development.
- Global Approval: Pergoveris has already received approval in 74 countries.
Fertility Drug Commitment
In exchange for the voucher, EMD Serono has agreed to lower the prices of its current fertility medications. This move is part of a broader initiative to improve patient access to vital treatments.
Conclusion
The announcement from the FDA marks a significant step in encouraging pharmaceutical companies to contribute to national health priorities. With the focus on vital therapies, patients can expect a quicker pathway to access essential medications.
